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“Expected practice” is a recently described method to alter clin-
ical behavior. We implemented an expected practice around 
short-course antibiotic therapy, which was associated with 
decreased antibiotic utilization for multiple bacterial infections. 
Thus, we describe this expected practice as a novel, simple, and 
inexpensive tool to enhance antibiotic stewardship.
Keywords. antibiotic stewardship; expected practice; qual-
ity improvement.
Society faces an ongoing crisis of antibiotic resistance, fueled by 
overuse of antibiotics. Nevertheless, recent studies have found 
that antibiotics are increasingly prescribed [1–3]. New strate-
gies, particularly psychological tools to alter provider behavior, 
are needed to enhance the effectiveness of antibiotic steward-
ship efforts [4, 5].
One way to improve antibiotic utilization is to prescribe 
courses for only as long as necessary to optimize cure rates 
[6, 7]. Multiple randomized controlled trials have found that 
shorter courses of antibiotic therapy result in similar cure rates 
as traditional courses for many types of infections, including 
urinary tract infections (UTIs), skin and soft tissue infections 
(SSTIs), and pneumonia (PNA) [7]. Unfortunately, familiar-
ity with short-course therapy as a stewardship tool is limited. 
A recent study found that only one-third of infectious diseases 
practitioners from 58 countries recommended short-course 
therapies [8]. Furthermore, primary providers may be con-
cerned that they, and not the stewardship team, face the conse-
quence of adverse outcomes of treatment decisions. Thus, fear 
of being blamed for the consequences of shortening durations 
of therapy, combined with lack of familiarity of evidentiary 
basis, may inhibit uptake of this stewardship tool.
One mechanism that can simultaneously educate providers 
regarding evidenced-based practice while also establishing an 
institutional requirement for standard practice is “expected prac-
tice” (EP) [9]. Expected practices set an institution’s expectation 
for how its providers practice medicine, and hence set stronger 
standards of care compared with clinical guidelines, which are 
typically viewed more as literature-based suggestions or expert 
consensus. Expected practices are developed and implemented 
by coalitions of primary and specialty care experts and approved 
by system-wide leadership committees, so they take on official 
expectations of the medical staff and hospital leadership. We 
developed and implemented a novel expected practice for short-
er-term antibiotic courses for standard infections. We sought 
to determine the impact of this expected practice on antibiotic 
prescribing behavior at our large, tertiary care, public hospital.
METHODS
Development and Implementation of the Expected Practice
Our expected practice on antibiotic durations (Supplementary 
Figure 1) was developed with input from primary care and infec-
tious diseases committees, with final approval by the hospital’s 
Pharmacy and Therapeutics Committee and Medical Executive 
Committee. The expected practice was then posted electroni-
cally on the hospital’s intranet and disseminated via memo from 
the hospital’s Chief Medical Officer to all credentialed provid-
ers. Hospital-wide implementation began in October 2016, and 
the only form of subsequent reinforcement was through the ex-
isting daily stewardship rounds.
Existing Antibiotic Stewardship Activities
Our institutional antimicrobial stewardship program (ASP) 
includes prospective audit and feedback, antimicrobial restric-
tion, and de-escalation rounds. There were no changes to this 
program during the baseline and interventional study periods. 
The only other new antibiotic stewardship initiative that started 
contemporaneously at the hospital was procalcitonin testing, 
which was implemented December 2016, after the expected 
practice was implemented.
Study Design and Setting
We conducted this quasi-experimental, pre/post quality 
improvement study at the Los Angeles County + University 
of Southern California (LAC+USC) Medical Center, a 676-
bed public teaching hospital in downtown Los Angeles. The 
study was determined to be not human subjects research by 
the University of Southern California Health Sciences Campus 
Institutional Review Board.
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We established baseline outcomes by collecting all adult 
(age > 18 years) inpatient visits for a 12-month period before ex-
pected practice implementation in October 2016 (patient visits 
with a discharge date between October 1, 2015, and September 
30, 2016). We treated the month of October as a burn-in period 
for the newly implemented expected practice and collected in-
patient visits for the following 12  months (patient visits with 
a discharge date between November 1, 2016, and October 31, 
2017). Any patients whose inpatient visit spanned both the 
baseline and the postimplementation period were excluded.
We selected patients for inclusion if any of the first 20 discharge 
diagnoses included ICD-10 codes for the 4 infectious diseases of 
interest: UTIs (cystitis N30.0*/N30.9*; UTI N39.0; pyelonephritis 
N10), SSTIs (cutaneous abscess L02; cellulitis L03), PNA (J13-
J18), and ventilator-associated pneumonia (VAP; J95.851).
Main Outcome and Measures
Our primary outcome measure was antibiotic days of therapy 
(DOT) [10]. We defined DOT as the sum total of days of each 
antibiotic administered as an inpatient plus the outpatient days 
prescribed upon hospital discharge (ie, 2 antibiotics given for 
10 days = 20 DOT). Our secondary outcome was total antibiotic 
exposure, defined as the sum total of milligrams of antibiotics 
administered as an inpatient plus the milligrams prescribed as 
an outpatient upon discharge from the hospital.
Statistical Analysis
We reported patient characteristics using summary statistics 
without inferential measures [11]. To adjust for covariates, we 
used a 0-truncated negative binomial multivariable regression 
to deal with overdispersion in the data. For each infection type, 
we modeled average duration of antibiotic therapy as a function 
of the presence of the expected practice in a pre/post fashion. 
For the primary analysis, we censored the small number of 
patients who had DOTs >90 days as being reflective of unusually 
complex hospital courses not relevant to the expected practice; 
we also ran a sensitivity analysis censoring >30 days of DOTs, 
and this did not meaningfully change the results. We adjusted 
for covariates (age, gender, insurance status, in-hospital mor-
tality, and use of procalcitonin testing) and for severity of illness 
using a number of risk adjustment measures (Medicare Severity 
Diagnosis Related Group Relative Weights, intensive care unit 
days, in-hospital mortality, and expected mortality according 
to the 2017 Mortality Expected Risk Model from the Vizient 
Consortium, Irving, TX). We assessed in-hospital mortality as a 
balancing/safety measure, to determine if shortening antibiotic 
therapy resulted in patient harm, by logistic regression.
RESULTS
The patients in the pre- and post-EP periods were similar 
demographically and with respect to disease severity (Table 1). 
When adjusting for all covariates of interest, average antibiotic 
DOT and antibiotic dose exposures significantly decreased for 
each of the studied diseases after introduction of the expected 
practice (Table 2). The point estimate of the decrease in average 
antibiotic DOT was 10%, 11%, 11%, and 27% for UTIs, SSTIs, 
pneumonia, and VAP, respectively (Table 1). Decreases in anti-
biotic exposure (mg) were larger, at 17%, 13%, 29%, and 35% for 
UTIs, SSTIs, pneumonia, and VAP, respectively.
We ran a sensitivity analysis to determine if the intervention’s 
impact waned over time (change in duration of therapy in the 
second half of intervention vs baseline year compared with first 
half of intervention vs baseline year). For UTIs and PNAs, we 
found no significant difference in the shortening of therapy in 
the second half of the intervention year. For SSTIs and VAPs, 
the shortening of therapy was not statistically significant in the 
second half of the intervention vs baseline year compared with 
Table 1. Characteristics of the Patients at Baseline and Postintervention
Variable Baseline Postintervention
Patient visits, No.
 UTI 1562 1512
 SSTI 1378 1292
 PNA 1184 1250
 VAP 55 73
Age, median (IQR), y
 UTI 57 (45 to 68) 57 (43 to 68)
 SSTI 50 (39 to 58) 49.5 (38 to 58)
 PNA 57 (46 to 68) 57 (47 to 67)
 VAP 54 (37 to 64) 56 (40 to 64)
Female gender, No. (%)
 UTI 913 (58) 880 (58)
 SSTI 367 (27) 359 (28)
 PNA 432 (36) 463 (37)
 VAP 15 (27) 20 (27)
Medicaid/Medicare, %/%
 UTI 72/20 73/21
 SSTI 82/8 79/12
 PNA 69/21 70/21
 VAP 64/22 71/18
DRG relative weight, median (IQR)
 UTI 1.16 (0.98 to 1.79) 1.17 (0.93 to 1.77)
 SSTI 1.11 (0.84 to 1.75) 1.27 (0.84 to 1.77)
 PNA 1.79 (1.43 to 2.63) 1.77 (1.32 to 2.45)
 VAP 5.13 (2.30 to 10.94) 5.11 (3.25 to 10.92)
Expected mortality,  
median (IQR), %
 UTI 0.75 (0.18 to 2.2) 0.75 (0.18 to 2.4)
 SSTI 0.18 (0.05 to 0.88) 0.19 (0.05 to 1.05)
 PNA 1.4 (0.55 to 5.7) 1.5 (0.50 to 5.6)
 VAP 10.3 (1.3 to 24.3) 10.4 (2.1 to 30.5)
Procalcitonin ordered, No. (%)
 UTI N/A 276 (18)
 SSTI N/A 157 (12)
 PNA N/A 587 (47)
 VAP N/A 47 (64)
Abbreviations: DRG, diagnostic-related group; IQR, interquartile range; PNA, pneumonia; 
SSTI, skin and skin structure infection; UTI, urinary tract infection; VAP, ventilator-associated 
pneumonia. 
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the first half; however, the duration still trended shorter in the 
second half of the intervention vs baseline year, and the analysis 
was underpowered as it was based on only half a year of data.
Interestingly, use of procalcitonin testing was associated with 
increased antibiotic DOT and dose exposure, and this effect was 
statistically significant in all disease groups except SSTIs. Thus, 
initiation of procalcitonin testing did not confound the improve-
ments in antibiotic utilization observed in the intervention period. 
Finally, mortality did not change postintervention (Table 1).
DISCUSSION
We describe a substantial reduction in duration of therapy for 
common, acute bacterial infections after introduction of an 
expected practice, with no change in mortality. We chose to use 
an expected practice around durations of therapy because provid-
ers expressed concern that they would be individually exposed to 
blame if they prescribed short-course antibiotic therapy and the 
clinical outcome was bad. The expected practice document lists 
the randomized controlled trials that underpin the expectation in 
practice. It also sets a standard of practice that the medical staff of 
the hospital and hospital leadership expect to be complied with 
unless specific contrary circumstances are documented in the 
chart. As such, the expected practice has alleviated concerns by 
our providers regarding both what the evidentiary basis of the 
practice is and the knowledge that they are acting in compliance 
with practice standards our institution has set. The expected 
practice required no technology and cost no money to implement 
other than the time spent by the various committees to develop 
the document and time spent by the ASP team reinforcing it on 
daily rounds. As these activities were done as part of the normal 
functions of each committee and ASP member, there were no 
additional time costs above and beyond routine function.
We were surprised to note that patients for whom procalci-
tonin testing was ordered generally experienced longer dura-
tions of antimicrobial therapy. These results contrast with a 
recent meta-analysis, which found that incorporation of pro-
calcitonin results and guidelines into clinical practice reduced 
antibiotic durations by approximately 25% [12]. The most likely 
explanation for this discrepancy is confounding by indication, 
as procalcitonin was ordered at the providers’ clinical discretion 
rather than being randomized. Thus, patients for whom procal-
citonin was ordered likely had more complex illness.
A limitation of this study design is the potential for the 
intervention to create a Hawthorne effect, wherein clinicians 
Table 2. Change in Antibiotic Utilization in Patients Pre-EP vs Post-EP 
Variable Baseline Postintervention Difference, P Value
Mean EP antibiotic DOT (IQR), d
 UTI 14.3 (13.7 to 15.0) 12.9 (12.4 to 13.5) –1.4 (–2.3 to –0.6); P = .001
 SSTI 20.0 (19.2 to 20.9) 17.9 (17.1 to 18.7) –2.2 (–3.3 to –1.0); P < .001
 PNA 18.0 (17.2 to 18.8) 16.0 (15.3 to 16.7) –2.0 (–3.2 to –0.9); P = .001
 VAP 36.1 (31.5 to 40.8) 26.5 (23.6 to 29.4) –9.6 (–16.0 to –3.3); P = .003
Mean EP antibiotic exposure (IQR), mg
 UTI 22 328 (21 247 to 23 408) 18 609 (17 693 to 19 526) –3718 (–5185 to –2252); P < .001
 SSTI 41 024 (38 974 to 43 073) 35 619 (33 778 to 37 460) –5404 (–8227 to –2582); P < .001
 PNA 33 078 (31 108 to 35 048) 23 647 (22 283 to 25 011) –9430 (–12 028 to –6833); P < .001
 VAP 97 185 (79 041 to 115 329) 62 938 (53 209 to 72 668) –34 246 (–57 507 to –10 986); P = .004
Mean procalcitonin antibiotic DOT (IQR), d*
 UTI 13.3 (12.9 to 13.7) 17.4 (15.5 to 19.2) +4.0 (2.2 to 5.9); P < .001
 SSTI 18.9 (18.3 to 19.5) 20.3 (17.7 to 22.8) +1.4 (–1.3 to 4.0); P = .3
 PNA 16.5 (15.9 to 17.0) 18.4 (17.2 to 19.6) +1.9 (0.5 to 3.3); P = .01
 VAP 26.7 (24.0 to 29.4) 37.5 (32.2 to 42.8) +10.8 (4.1 to 17.5); P = .002
Mean procalcitonin antibiotic exposure (IQR), mg*
 UTI 19 659 (18 967 to 20 350) 29 915 (26 297 to 33 532) +10 256 (6537 to 13 975); P < .001
 SSTI 38 515 (37 120 to 39 910) 35 223 (29 861 to 40 585) –3292 (–8868 to 2285); P = .2
 PNA 26 347 (25 158 to 27 537) 33 115 (30 197 to 36 032) +6768 (3447 to 10 088); P < .001
 VAP 64 947 (55 653 to 74 242) 99 129 (78 793 to 119 464) +34 181 (9265 to 59 097); P = .007
In-hospital mortality, No. (%)
 UTI 62 (4) 74 (5) OR, 1.1 (IQR, 0.7 to 1.6); P = .6
 SSTI 17 (1) 18 (1) OR, 0.9 (IQR, 0.4 to 1.9); P = .7
 PNA 131 (11) 151 (12) OR, 1.1 (IQR, 0.8 to 1.5); P = .4
 VAP 13 (24) 17 (23) OR, 0.9 (IQR, 0.3 to 2.6); P = .9
Abbreviations: DOT, days of therapy; DRG, diagnostic-related group; EP, expected practice; IQR, interquartile range; OR, odds ratio; PNA, pneumonia; SSTI, skin and skin structure infection; 
UTI, urinary tract infection; VAP, ventilator-associated pneumonia. 
aProcalcitonin data are not stratified as baseline vs post-EP time periods, but rather by use of procalcitonin testing (left column = no procalcitonin test sent, right column = with procalcitonin 
test).
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improve their prescribing behavior because they know they 
are being monitored. However, such an effect would still be 
a positive impact of the intervention if it could be sustained. 
Our sensitivity analysis showed no evidence of waning effect 
for UTIs or PNAs; a possible waning effect was seen for SSTIs 
and VAP; however, the intervention still trended toward 
benefit vs the baseline period in the second half of the year, 
despite smaller sample sizes and an underpowered compari-
son (only half the year). Another limitation is lack of data on 
infection relapses or readmissions. Nevertheless, we found no 
change in mortality, and short-course antibiotic interventions 
have been found safe to implement in multiple randomized 
controlled trials [7].
In summary, we report that implementation of an expected 
practice for shorter-course antibiotic regimens, supported 
by our antibiotic stewardship team, was associated with 
a marked decrease in antibiotics prescribed for common, 
acute bacterial illnesses. Expected practice is a promising 
new psychological tool to promote effective antimicrobial 
stewardship.
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